Business
Vetoquinol: 2025 Annual Results
LURE, France, March 27, 2026--Regulatory News: Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, "In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on th
About this update from Vetoquinol Sa
[{"type":"text","content":"Annual sales: €526 m (+0.2% at constant exchange rates)Essential Products sales: €334 m (+4.1% at constant exchange rates)EBIT before amortization of acquired assets: €92 m (17.4% of sales)Net result, Group share: €57 m (10.9% of sales)Cash flow generation: €72 m","length":267,"tagName":"p"},{"type":"text","content":"LURE, France, March 27, 2026--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, "In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on the territory expansion of our Essentials."","length":504,"tagName":"p"},{"type":"text","content":"The Board of Directors of Vetoquinol SA, meeting on March 25, 2026, reviewed the company’s performance and approved the financial statements for the 2025 fiscal year. The audit procedures are currently being finalized by the Statutory Auditors.","length":244,"tagName":"p"},{"type":"text","content":"In an environment marked by unprecedented currency impacts, Vetoquinol continued to improve its product mix by expanding its Essentials ranges—the core of its strategy—and simplifying its complementary product ranges. It also reignited growth momentum in the United States, the company’s largest market, and completed, on schedule, the transfer of production for the parasiticides acquired in 2020.","length":398,"tagName":"p"},{"type":"text","content":"Sales for fiscal year 2025 came in at €525.7 million, representing a slight growth at constant exchange rates (+0.2%). On a reported basis, it declined by 2.5%, impacted by historically high negative currency effects (€14.8 million) and the program to streamline the Complementary product ranges (-€9.7 million). Excluding these items, sales increased by +2.1%.","length":361,"tagName":"p"},{"type":"text","content":"Essential products, at €334.5 million, continued to show solid growth (+4.1% at constant exchange rates), driven by a strong fourth quarter with growth of +8% at constant exchange rates. They now accoun...